Phospho-JAK1 (Tyr1022) Polyclonal Antibody
Price:
Size:
120μL
60μL
20μL
- 宿主: Rabbit
- 反应性: Human;Mouse;Rat
- 应用性: WB;IHC-p;IF
Verified Samples |
Verified Samples in WB:A549 Verified Samples in IHC:Human liver cancer Verified Samples in IF:Mouse liver |
Dilution | WB 1:500-1:2000;IHC 1:100-1:300;IF 1:50-1:200 |
Clonality | Polyclonal |
Isotype | IgG |
Immunogen | Synthesized peptide derived from human JAK1 around the phosphorylation site of Tyr1022 |
Abbre | JAK1 (phospho Tyr1022) |
Synonyms | JAK 1;JAK 1A;JAK 1B;JAK-1;JAK1;JAK1;JAK1A;JAK1B;Janus kinase 1 (a protein tyrosine kinase);Janus kinase 1;JTK3;Tyrosine protein kinase JAK 1;Tyrosine protein kinase JAK1;Tyrosine-protein kinase JAK1抗体 |
Swissprot | |
Calculated MW | 132kDa |
Observed MW | 132kDa |
Cellular Localization | Endomembrane system. Wholly intracellular, possibly membrane associated. |
Tissue Specificity | Expressed at higher levels in primary colon tumors than in normal colon tissue. The expression level in metastatic colon tumors is comparable to the expression level in normal colon tissue. |
Concentration | 1 mg/mL |
Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
Buffer | PBS with 0.02% sodium azide, 0.5% protective protein and 50% glycerol, pH7.4 |
Purification Method | Affinity purification |
Research Areas | Cancer; Cell Biology; Epigenetics and Nuclear Signaling; Signal Transduction |
Conjugation | Unconjugated |
Background | Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor. |
Western Blot analysis of A549 cells with Phospho-JAK1 (Tyr1022) Polyclonal Antibody at dilution of 1:500
Immunohistochemistry of paraffin-embedded Human liver cancer tissue with Phospho-JAK1 (Tyr1022) Polyclonal Antibody at dilution of 1:200
Immunofluorescence analysis of Mouse liver tissue with Phospho-JAK1 (Tyr1022) Polyclonal Antibody at dilution of 1:200
-
Candesartan Attenuates Cisplatin-Induced Lung Injury by Modulating Oxidative Stress, Inflammation, and TLR-4/NF-κB, JAK1/STAT3, and Nrf2/HO-1 Signaling
IF: 5.215Journal:Pharmaceuticals -
Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non‑small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway
IF: 3.906Journal:ONCOLOGY REPORTS